

The benefit of combining hydroxychloroquine with quin

patients

Lupus

9, 92-95

DOI: [10.1191/096120300678828082](https://doi.org/10.1191/096120300678828082)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Is there a role for quinacrine (Atabrine) in the new millennium?. <i>Lupus</i> , 2000, 9, 81-82.	0.8	20
2	Treatment of systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2001, 1, 1065-1075.	1.7	29
3	Therapy of cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2001, 14, 61-69.	0.8	6
4	Decreased production of interleukin-12 and interferon- γ is associated with renal involvement in systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2001, 30, 159-163.	0.6	42
5	Antimalarial therapy: a panacea for mild lupus?. <i>Lupus</i> , 2001, 10, 148-151.	0.8	36
6	Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. <i>Lupus</i> , 2002, 11, 71-81.	0.8	64
7	Management of lupus erythematosus: recent insights. <i>Current Opinion in Rheumatology</i> , 2002, 14, 212-219.	2.0	32
8	Management of skin disease in patients with lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 245-264.	1.4	37
9	New therapies in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 293-312.	1.4	13
10	Quinacrine and hydroxychloroquine, a forgotten combination for patients with active systemic lupus erythematosus in Australasia?. <i>APLAR Journal of Rheumatology</i> , 2003, 6, 37-39.	0.2	0
11	Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. <i>Lupus</i> , 2003, 12, 297-301.	0.8	14
12	Systemic lupus erythematosus vasculitis: A current therapeutic overview. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 87-97.	0.4	13
13	Management of "refractory" skin disease in patients with lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 767-784.	1.4	36
14	Antimalarials. , 2005, , 347-372.		0
15	Combination Antimalarials in the Treatment of Cutaneous Dermatomyositis. <i>Archives of Dermatology</i> , 2005, 141, 855-9.	1.7	78
17	Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 1-11.	3.3	37
18	High-Dose Intravenous Immunoglobulins: An Option in the Treatment of Systemic Lupus Erythematosus. <i>Human Immunology</i> , 2005, 66, 395-402.	1.2	71
19	Subacute Cutaneous Lupus Erythematosus: A Quarter Century's Perspective. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006, 5, 65-86.	0.1	3

#	ARTICLE	IF	CITATIONS
21	Lupus erythematosus: systemic and cutaneous manifestations. <i>Clinics in Dermatology</i> , 2006, 24, 348-362.	0.8	151
22	The Reduction of Serum B-Lymphocyte Activating Factor levels following Quinacrine Add-On Therapy in Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 2006, 63, 299-303.	1.3	39
23	Therapy of cutaneous lupus erythematosus. <i>Expert Review of Dermatology</i> , 2006, 1, 105-120.	0.3	2
24	B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?. <i>Clinical Rheumatology</i> , 2007, 26, 1701-1704.	1.0	27
25	Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. <i>Lupus</i> , 2009, 18, 735-739.	0.8	68
26	Cutaneous Lupus Erythematosus. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 365-381.	3.3	234
27	Treatment of cutaneous lupus erythematosus. <i>Lupus</i> , 2010, 19, 1125-1136.	0.8	46
28	Quinacrine in the Treatment of Cutaneous Lupus Erythematosus: Practical Aspects and a Case Series. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 54-58.	0.2	2
30	Antimalarials and SLE. , 2011, , 1061-1081.		2
32	Elimination of autoreactive B cells in humanized SCID mouse model of SLE. <i>European Journal of Immunology</i> , 2011, 41, 3301-3311.	1.6	18
33	Optimizing Antimalarial Therapy for Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , 2011, 147, 1267.	1.7	4
34	Humanized SCID Mice Models of SLE. <i>Current Pharmaceutical Design</i> , 2011, 17, 1261-1266.	0.9	8
35	Response to Antimalarial Agents in Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , 2011, 147, 1261.	1.7	123
36	Hypertrophic and Ulcerated Discoid Lupus Erythematosus. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 453-457.	0.6	3
37	Generation of Gene-Engineered Chimeric DNA Molecules for Specific Therapy of Autoimmune Diseases. <i>Human Gene Therapy Methods</i> , 2012, 23, 357-365.	2.1	4
38	Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. <i>Clinical Rheumatology</i> , 2013, 32, 1619-1626.	1.0	42
39	Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus. <i>British Journal of Dermatology</i> , 2013, 169, 653-659.	1.4	22
40	Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?. <i>Acta Dermato-Venereologica</i> , 2015, 95, 596-599.	0.6	10

#	ARTICLE	IF	CITATIONS
41	Quinacrine: A Treatment Option That Should Not Be Overlooked. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 867-870.	0.2	1
42	Quinacrina, un escalón terapéutico que no debemos obviar. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 867-870.	0.2	1
43	The skin in autoimmune diseases—Unmet needs. <i>Autoimmunity Reviews</i> , 2016, 15, 948-954.	2.5	17
44	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 413.e1-413.e14.	0.1	7
47	Quinacrine Suppresses Tumor Necrosis Factor- α and IFN- γ in Dermatomyositis and Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S57-S63.	0.8	33
48	Traditional DMARDs. , 2017, , 958-982.e7.		3
49	Combined mepacrine—hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. <i>Lupus</i> , 2018, 27, 1718-1722.	0.8	24
50	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	0.9	247
51	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. <i>Current Opinion in Rheumatology</i> , 2018, 30, 482-489.	2.0	52
52	Effectiveness of Quinacrine (Mepacrine) in Photosensitive Autoimmune Diseases, Lupus Erythematosus, and Dermatomyositis: Report on 38 Cases and Literature Review. <i>Archives of Rheumatology</i> , 2019, 34, 34-43.	0.3	4
54	Editorial: Quinacrine: au Revoir or Adieu? This safe and effective drug should be reintroduced. <i>Current Opinion in Rheumatology</i> , 2021, 33, 219-220.	2.0	0
55	Targeting Toll-like Receptor (TLR) Pathways in Inflammatory Arthritis: Two Better Than One?. <i>Biomolecules</i> , 2021, 11, 1291.	1.8	12
56	Antimalarial drugs (and lupus). , 2021, , 601-609.		0
57	Traditional DMARDs. , 2013, , 917-940.e6.		2
58	Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. <i>Oncotarget</i> , 2017, 8, 228-237.	0.8	12
62	Tratamiento del lupus cutáneo con quinacrina: una serie de 6 casos. <i>Piel</i> , 2020, 35, 278-279.	0.0	0